INCY Stock Cash Flow Statements

Incyte Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Incyte Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-09-30	2014-06-30	2014-03-31	2013-09-30	2013-06-30	2013-03-31	2012-09-30	2012-06-30	2012-03-31	2011-09-30	2011-06-30	2011-03-31	2010-09-30	2010-06-30	2010-03-31	2009-09-30	2009-06-30	2009-03-31	2008-09-30	2008-06-30	2008-03-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30	2004-03-31	2003-09-30	2003-06-30	2003-03-31	2002-09-30	2002-06-30	2002-03-31

cash flows from operating activities:
net income	404,999,000	158,203,000	201,212,000	106,456,000	-444,601,000	169,548,000	201,079,000	171,269,000	203,548,000	21,703,000	28,461,000	112,775,000	161,432,000	37,992,000	563,851,000	181,739,000	149,456,000	53,535,000	149,850,000	-15,203,000	290,298,000	-720,642,000	111,005,000	128,271,000	105,318,000	102,312,000	69,063,000	29,176,000	52,394,000	-41,140,000		36,054,000	-12,484,000	-187,083,000		36,877,000	34,425,000	24,047,000	55,176,000	-39,582,000	9,296,000	-18,359,000	59,292,000	-36,873,000	-33,957,000	-22,036,000	-2,571,000	-15,669,000	-21,710,000	4,037,000	-45,426,000	-53,078,000	-51,871,000	-26,512,000	-31,702,000	3,044,000	-35,729,000	-43,357,000	-40,035,000	-40,036,000	-44,794,000	-45,564,000	-40,157,000	-24,494,000	-18,439,000	-22,147,000		-15,837,000	-20,520,000	-17,306,000		-30,211,000	-25,145,000	-20,131,000	-37,526,000	-25,976,000	-63,600,000	-37,715,000	-43,012,000	-26,900,000	-55,784,000	-38,411,000	-17,541,000	-13,441,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	22,919,000	22,362,000	22,733,000	22,520,000	22,048,000	21,947,000	21,762,000	21,390,000	20,297,000	19,211,000	18,218,000	16,692,000	16,507,000	16,438,000	14,858,000	14,691,000	14,457,000	13,838,000	13,166,000	12,949,000	12,594,000	13,098,000	13,345,000	13,862,000	13,435,000	13,891,000	14,226,000	13,818,000	13,501,000	13,424,000		11,940,000	12,352,000	15,027,000		16,951,000																6,871,000	6,647,000	6,430,000	5,378,000	5,885,000	6,396,000	4,273,000	2,636,000	2,509,000	3,250,000	3,272,000	3,288,000	3,253,000	3,261,000	3,199,000	3,271,000	1,302,000	1,229,000	1,609,000	1,676,000	3,955,000	708,000	1,853,000	2,928,000	4,143,000	3,597,000	3,245,000	4,504,000	4,482,000	4,457,000	5,609,000	5,885,000	5,369,000
stock-based compensation	64,609,000	60,982,000	71,718,000	77,922,000	56,640,000	59,778,000	59,990,000	48,000,000	54,520,000	53,379,000	52,679,000	45,404,000	46,496,000	43,841,000	48,222,000	42,694,000	44,732,000	47,358,000	45,261,000	43,800,000	46,303,000	42,513,000	42,023,000	43,359,000	40,615,000	40,592,000	37,323,000	38,001,000	36,605,000	36,224,000		34,929,000	33,745,000	30,613,000		26,527,000	21,302,000	20,769,000	17,097,000	17,625,000	17,592,000	17,558,000	15,428,000	15,478,000	15,347,000	9,447,000	9,933,000	9,197,000	9,583,000	9,911,000	9,932,000	7,399,000	7,191,000	6,946,000	4,059,000	3,555,000	3,121,000	2,196,000	2,497,000	3,360,000	3,857,000	3,945,000	3,345,000	2,631,000	2,601,000	2,210,000	2,250,000	2,059,000	2,254,000	2,327,000	34,000	50,000	51,000	51,000
deferred income taxes	116,777,000	-6,706,000	56,000	-33,876,000	-17,482,000	-34,251,000	-65,979,000	-31,055,000	-39,701,000	-22,163,000	16,659,000	7,957,000	30,369,000	2,106,000	-465,426,000	-18,000
other	-8,512,000	5,292,000	-4,229,000	-7,412,000	-366,000	2,954,000	23,122,000	3,127,000	-1,019,000	-2,651,000		6,630,000	6,376,000	2,091,000	-3,851,000	2,054,000	-1,408,000	4,622,000	-8,152,000	131,000	8,422,000	145,000	130,000	129,000	123,000	104,000	86,000	86,000	85,000	87,000		70,000	75,000	71,000		74,000	73,000	178,000																																													1,223,000	-1,150,000
gain on equity investments	4,151,000	1,343,000
loss on change in fair value of acquisition-related contingent consideration			-4,044,000	23,410,000					8,374,000	6,196,000
changes in operating assets and liabilities:
accounts receivable	-20,229,000	30,955,000	-96,693,000	-19,400,000	6,476,000	-1,969,000	-86,294,000	-19,269,000	-14,206,000	21,091,000	-26,691,000	64,780,000	-120,624,000	53,956,000	-99,611,000	-78,519,000	-40,813,000	84,637,000	-117,529,000	64,068,000	-77,011,000	-42,713,000	-32,693,000	26,564,000	-58,599,000	63,517,000	-59,862,000	68,574,000	-96,120,000	46,109,000		-28,829,000	75,459,000	-96,217,000		-3,894,000	-15,988,000	13,170,000	-27,484,000							-5,675,000	519,000	42,910,000				-86,000			1,625,000	-1,107,000	158,408,000	-54,000	-68,000	311,000	-92,000	53,000	711,000	-9,000	173,000	633,000		-44,000			-376,000	-115,000	1,616,000	-404,000	31,000	657,000	573,000	1,824,000	-2,664,000	318,000	652,000	10,349,000	2,562,000	26,347,000
prepaid expenses and other assets	-86,395,000	-62,045,000	65,746,000	-15,633,000	-38,050,000	-1,698,000	19,590,000	-53,862,000	16,135,000	-24,354,000	9,277,000	-14,636,000	-11,409,000	-13,971,000	-39,296,000	-21,803,000	7,796,000	-10,777,000	3,334,000	279,000	5,038,000	-16,701,000	-4,255,000	1,645,000	2,795,000	5,559,000	-12,082,000	2,259,000	-4,667,000	-18,922,000		1,441,000	-8,398,000	-25,094,000		-5,863,000	-3,793,000	-3,667,000	5,501,000	-2,864,000						-832,000			-78,000	8,419,000	29,000	-1,638,000			1,142,000			-113,000	2,553,000	380,000				1,037,000	-254,000	1,949,000	-2,781,000	643,000	1,130,000	1,594,000	-1,810,000	-349,000	1,284,000	877,000	-4,293,000	807,000	3,098,000	901,000	-3,980,000	4,671,000	-1,184,000	-2,189,000	-2,046,000	-2,138,000
inventory	-19,525,000	-28,574,000	-34,281,000	-8,376,000	-27,779,000	-57,197,000	-92,958,000	-23,757,000	-20,116,000	-33,320,000	-19,188,000	-11,126,000	-23,287,000	-13,903,000	-4,750,000	72,000	-11,881,000	-4,406,000	-10,264,000	180,000	-3,672,000	-5,712,000	-3,187,000	-625,000	-1,688,000	-600,000	1,013,000	1,152,000	-1,000	1,879,000		279,000	3,672,000	790,000		2,757,000	930,000	752,000	928,000			1,000									23,000
accounts payable	19,911,000	-2,159,000	19,050,000	30,536,000	-16,064,000	54,637,000	-29,810,000	-16,127,000	99,905,000	-221,913,000	114,371,000	-31,595,000	42,223,000	-19,563,000	57,601,000	-7,591,000	37,042,000	-13,709,000	-23,745,000	31,603,000	29,972,000	-22,710,000	-11,729,000	23,792,000	1,221,000	-33,464,000	8,349,000	19,919,000	1,444,000	6,444,000		840,000	-17,234,000	10,728,000		16,800,000	7,069,000	1,814,000	2,719,000	-1,796,000	2,576,000	2,124,000	-646,000					1,554,000													-16,000	253,000	5,422,000				2,212,000	-1,673,000	-532,000	2,336,000	-799,000	189,000	1,861,000	1,000	-651,000	-2,060,000	-480,000	-960,000	1,741,000	-2,050,000	-2,415,000	-1,231,000	1,962,000	-862,000
accrued and other liabilities	-476,725,000	74,842,000	129,769,000	121,742,000	-78,037,000	105,465,000	116,223,000	21,891,000	20,600,000	71,900,000	47,812,000	120,733,000	-2,136,000	53,787,000	46,402,000	91,419,000	-4,144,000	-2,238,000	51,646,000	23,992,000	23,658,000	14,546,000	29,989,000	32,476,000	38,507,000	-21,930,000	-3,466,000	11,494,000	-12,782,000	-7,273,000		23,787,000	2,209,000	10,227,000		24,546,000	-39,207,000	29,679,000	8,776,000	8,603,000	6,676,000	1,190,000
net cash from operating activities	44,741,000	266,067,000	381,218,000	310,871,000	-575,563,000	218,811,000	147,729,000	147,835,000	306,526,000	-105,603,000	283,662,000	296,381,000	174,157,000	215,741,000	115,351,000	255,098,000	172,944,000	206,095,000	107,321,000	182,115,000	269,382,000	-683,417,000	131,618,000	270,415,000	152,960,000	155,663,000	83,838,000	199,148,000	32,403,000	20,838,000		53,123,000	116,794,000	-173,638,000		95,271,000	17,572,000	97,535,000	70,009,000	7,723,000						-11,950,000	8,081,000	24,738,000							-29,522,000	-2,766,000	102,823,000													15,602,000				-26,273,000	-27,489,000	-24,734,000	-25,935,000	-36,509,000	-40,000,000	-15,623,000	-42,750,000	-23,837,000	-8,807,000	-6,020,000
cash flows from investing activities:
sale of equity investments	-1,000	8,000	1,915,000	55,609,000
capital expenditures	-19,074,000	-3,169,000	-17,384,000	-5,187,000	-54,143,000	-9,549,000	-2,267,000	-10,976,000	-7,337,000	-11,906,000	-21,273,000	-27,811,000	-11,743,000	-17,006,000	-34,463,000	-32,153,000	-66,307,000	-48,083,000	-51,433,000	-52,821,000	-43,860,000	-39,265,000	-29,315,000	16,812,000	-47,294,000	-18,267,000	-25,281,000	-24,821,000	-10,791,000	-12,590,000	-25,230,000	-34,304,000	-30,499,000	-20,967,000	-15,895,000	-16,629,000	-82,214,000	-5,562,000	-6,896,000																																			-95,000	-569,000	-362,000	-342,000	-118,000	-1,737,000	-1,375,000	-5,584,000	-3,776,000	-4,716,000	-1,995,000
free cash flows	25,667,000	262,898,000	363,834,000	305,684,000	-629,706,000	209,262,000	145,462,000	136,859,000	299,189,000	-117,509,000	262,389,000	268,570,000	162,414,000	198,735,000	80,888,000	222,945,000	106,637,000	158,012,000	55,888,000	129,294,000	225,522,000	-722,682,000	102,303,000	287,227,000	105,666,000	137,396,000	58,557,000	174,327,000	21,612,000	8,248,000		18,819,000	86,295,000	-194,605,000		78,642,000	-64,642,000	91,973,000	63,113,000																																			-26,368,000	-28,058,000	-25,096,000	-26,277,000	-36,627,000	-41,737,000	-16,998,000	-48,334,000	-27,613,000	-13,523,000	-8,015,000
payments for intangible assets			0	-12,500,000			0	0	0	-15,000,000
purchases of marketable securities	-56,110,000	-41,236,000	-29,384,000	-24,895,000	-38,283,000	-165,808,000	-233,792,000	-69,951,000	-97,390,000	-54,887,000	-20,802,000	-15,070,000			-6,997,000	-125,882,000	-62,987,000	-39,301,000	-98,176,000	-131,279,000	-140,016,000	-147,403,000	-152,652,000	-118,187,000	-69,396,000	-34,574,000	-55,704,000	-45,401,000	-20,794,000	-38,033,000		-16,665,000	-8,983,000	-106,271,000		-9,126,000	-1,000,000	-16,795,000	-13,776,000																			6,000			-23,000	-1,189,000	1,241,000											-86,155,000	-211,321,000	-148,917,000	-46,642,000	-423,614,000	-169,148,000	-201,290,000	-134,408,000	-205,096,000	-248,092,000	-120,222,000
maturities of marketable securities																																									21,250,000	19,274,000	134,000	157,000	90,000
net cash from investing activities	-18,872,000	1,097,000	-21,465,000	38,274,000	213,820,000	-73,112,000	-154,500,000	-17,189,000	-7,429,000	-28,559,000	-20,912,000	-28,402,000	-12,480,000	-16,748,000	-66,047,000				-102,730,000	-14,453,000	-43,258,000	-108,560,000	-30,028,000	12,284,000	-45,147,000	-24,563,000	-36,097,000	-17,876,000	-3,922,000	-28,528,000		-30,839,000	-37,318,000	-138,819,000				28,757,000	-4,529,000															24,000	855,000	9,674,000	6,516,000	5,995,000	3,949,000	3,066,000	9,372,000	2,927,000	90,749,000	85,648,000	28,563,000	26,694,000	16,307,000	-9,200,000	7,458,000	11,470,000	-10,235,000			-1,117,000	-5,288,000	-12,207,000	40,999,000	-100,664,000	35,285,000	25,889,000	30,589,000			59,061,000
cash flows from financing activities:
repurchases of common stock				-103,000
excise tax paid on repurchase of common stock
proceeds from issuance of common stock under stock plans	14,884,000	3,239,000	33,059,000	1,282,000	14,483,000	477,000	7,517,000	-48,000	14,379,000	13,988,000	18,126,000	5,297,000	21,294,000	16,398,000			11,016,000	20,028,000	18,709,000	7,783,000	69,194,000	14,619,000	29,516,000	3,111,000	15,191,000	15,481,000	9,462,000	2,437,000	15,448,000	2,595,000		9,093,000	15,725,000	33,736,000		8,363,000	13,886,000	10,219,000	9,565,000	13,913,000	33,778,000	29,180,000	6,539,000	12,779,000	44,833,000	28,364,000	9,780,000	17,777,000	8,914,000	17,894,000	13,421,000	1,073,000	12,512,000	4,129,000	3,383,000	2,434,000	4,227,000	282,000			550,000	1,562,000	520,000	74,000	844,000	95,000	431,000	23,000	716,000	238,000	536,000	86,000	819,000	48,000	2,907,000	1,137,000	2,026,000	761,000	91,000	1,109,000	8,000	1,271,000	1,774,000	2,871,000
tax withholdings related to restricted and performance share vesting	-912,000	-9,454,000	-886,000	-32,551,000	-691,000	-6,174,000	-489,000	-24,633,000	-675,000	-2,753,000	-577,000	-18,870,000	-4,693,000	-2,161,000
payment of finance lease liabilities	-1,155,000	-1,090,000	-1,037,000	-979,000	-911,000	-871,000	-837,000	-885,000	-836,000	-802,000	-756,000	-738,000	-700,000	-668,000	-629,000	-615,000	-600,000	-573,000	-217,000	-232,000	-200,000	-187,000	-196,000	-217,000	-214,000	-195,000
payment of contingent consideration	-4,963,000	-5,371,000	-10,742,000	0	-5,371,000	-5,845,000	-5,845,000	-11,690,000	0	-6,424,000	-19,273,000	0	0	-13,473,000	0	-6,736,000	-6,737,000	-6,620,000	-6,620,000	-6,620,000	-12,587,000	-11,933,000	0	0	-5,967,000	-10,799,000	-5,399,000	0				-4,486,000	-4,356,000	-3,679,000
net cash from financing activities	-11,246,000	-12,676,000	20,394,000	-32,351,000	-1,997,177,000	-12,413,000	346,000	-37,256,000	12,868,000	4,009,000	-2,480,000	-14,311,000	15,901,000	96,000	9,005,000	-19,343,000	3,679,000	12,835,000	11,872,000	931,000	56,407,000	2,499,000	29,320,000	2,894,000	9,010,000	4,487,000	4,063,000	2,437,000	5,562,000	2,595,000		654,011,000	10,491,000	21,944,000		7,126,000	27,763,000	9,884,000	10,158,000	13,612,000	31,160,000	32,686,000	6,644,000	12,779,000	44,537,000	26,873,000	9,000	17,777,000	8,914,000	17,894,000	13,421,000	1,073,000	12,512,000	4,129,000				281,034,000			102,261,000	1,562,000	520,000	74,000	844,000	95,000	-91,185,000	111,930,000	716,000	10,238,000				48,000	86,226,000	-37,275,000	2,026,000	243,261,000			-97,000	1,271,000	-2,898,000	2,926,000
effect of exchange rates on cash, cash equivalents, and restricted cash	-1,197,000	-552,000	3,458,000	128,000	13,000	-676,000
net increase in cash, cash equivalents, and restricted cash	13,426,000	253,936,000	383,605,000	316,922,000	-2,358,907,000	132,610,000
cash, cash equivalents, and restricted cash at beginning of period	0	1,689,451,000	0	0	0	3,215,221,000
cash, cash equivalents, and restricted cash at end of period	13,426,000	1,943,387,000	383,605,000	316,922,000	-2,358,907,000	3,347,831,000
supplemental schedule of cash flow information
income taxes paid	177,075,000	844,000	70,196,000	73,186,000	226,983,000	2,691,000	125,026,000	115,867,000	130,206,000	7,107,000	19,705,000	40,073,000	72,992,000	3,472,000	21,859,000	9,876,000	35,657,000	339,000	13,955,000	32,592,000	23,310,000	855,000	21,155,000	5,959,000	5,991,000	448,000	2,485,000	988,000	1,892,000	52,000		626,000	3,317,000	2,244,000		488,000										0
cash paid for contract dispute settlement
unpaid purchase of intangible asset
unpaid excise tax on repurchase of common stock		19,185,000	0	0
unpaid purchases of property and equipment	1,156,000	2,890,000	-941,000	2,738,000	417,000	383,000	5,041,000	-4,409,000	1,361,000	3,059,000	-5,343,000	-116,000	-6,812,000	15,764,000	3,206,000	-6,931,000	9,561,000	21,262,000	9,971,000	-1,981,000	1,235,000	13,582,000				8,414,000						-92,000	1,727,000	9,139,000
leased assets obtained in exchange for new operating lease liabilities	597,000	1,171,000	7,238,000	248,000			0	0	4,466,000	809,000	3,095,000	1,625,000	407,000	1,618,000	5,348,000	1,851,000	5,319,000	1,898,000	6,888,000	4,300,000	6,736,000	1,984,000	921,000	4,328,000	1,426,000	932,000
leased assets obtained in exchange for new finance lease liabilities	84,000	220,000	6,947,000	491,000	918,000	550,000	1,081,000	152,000	639,000	385,000	414,000	140,000	724,000	584,000	1,058,000	47,000	340,000	68,000	0	1,631,000			149,000	0	29,095,000	645,000
gain on change in fair value of acquisition-related contingent consideration		11,572,000
sale and maturities of marketable securities		45,494,000	23,388,000	25,247,000	80,389,000	102,245,000	81,559,000	73,738,000	97,298,000	53,189,000	21,163,000	14,479,000	43,251,000	258,000	261,000	124,136,000	71,901,000	35,213,000	46,879,000	156,933,000	136,082,000	173,576,000	151,939,000	113,659,000	71,543,000	28,278,000	44,888,000	52,346,000	27,662,000	31,032,000		20,130,000	2,164,000	112,310,000		13,923,000	12,778,000	51,114,000	16,143,000
realized and unrealized (gain) loss on equity investments
purchase of long term investments							0								-24,848,000	0			0	0	0	-95,468,000					0	0	1,000	-8,937,000		0	0	-123,891,000
repurchase of common stock																																																																															0	0	-105,000
realized and unrealized gain on equity investments				12,982,000
unrealized (gain) loss on long term investments						-99,947,000	-34,054,000	26,654,000															-15,755,000	-2,339,000						-22,679,000
(gain) loss on change in fair value of acquisition-related contingent consideration						-456,000
sale of long term investments							0	0	0	45,000					0	1,145,000
effect of exchange rates on cash, cash equivalents, restricted cash and investments								2,715,000	-1,891,000	-199,000		1,530,000	988,000	210,000	148,000	-1,559,000	172,000	-2,331,000	-2,136,000	2,532,000	993,000	1,560,000	-221,000	187,000	-284,000	126,000
net increase in cash, cash equivalents, restricted cash and investments								96,105,000	310,074,000	-130,352,000		255,198,000	178,566,000	199,299,000	58,457,000	201,442,000	127,650,000	156,846,000	14,327,000	171,125,000	283,524,000	-787,918,000	130,689,000	285,780,000	116,539,000	135,713,000	51,798,000	183,671,000
cash, cash equivalents, restricted cash and investments at beginning of period								0	0	2,953,120,000		0	0	2,059,160,000	0	0	0	1,514,765,000	0	0	0	1,833,707,000	0	0	0	1,164,986,000	0	0	0	900,434,000
cash, cash equivalents, restricted cash and investments at end of period								96,105,000	310,074,000	2,822,768,000	260,897,000	255,198,000	178,566,000	2,258,459,000	58,457,000	201,442,000	127,650,000	1,671,611,000	14,327,000	171,125,000	283,524,000	1,045,789,000	130,689,000	285,780,000	116,539,000	1,300,699,000	51,798,000	183,671,000	34,143,000	895,374,000
unrealized loss on long term investments										5,318,000		660,000	24,897,000	46,585,000				27,709,000									22,182,000	9,949,000					19,574,000	5,814,000
unrealized foreign exchange losses (gains) and other
unrealized gain on long term investments															-4,322,000	27,450,000				13,207,000	-72,274,000	48,132,000				-20,989,000
reclassification to common stock and additional paid in capital in connection with conversions of 1.25% convertible senior notes due 2020																			12,007,000	6,830,000												1,000	1,628,000	328,382,000		0	0	4,000
change in fair value of acquisition-related contingent consideration													3,313,000	6,382,000	1,673,000	2,910,000	4,632,000	5,526,000	3,595,000	7,109,000	6,054,000	6,627,000	3,122,000	3,281,000	6,608,000	6,671,000	7,465,000	4,720,000	7,303,000	6,685,000		-16,343,000	7,073,000	7,356,000		8,012,000
interest paid																			75,000	0			120,000	0			134,000	0				0				0	3,046,000	846,000	5,048,000	6,028,000	831,000	839,000	4,000			0
proceeds from issuance of common stock under stock plans net of tax withholding
net cash (used in) investing activities																	-49,145,000	-59,753,000
purchase of long term investment																		-8,662,000
sale of long term investment																		1,080,000	0	12,714,000
reclassification to common stock and additional paid in capital in connection with conversions of 0.375% convertible senior notes due 2018																											7,664,000	2,000	2,000	27,000		7,000	16,872,000	334,162,000
in-process research and development impairment
expense related to senior note conversions																																0	751,000	54,130,000
proceeds from issuance of common stock
cash paid in connection with senior note conversions																																0	-837,000	-8,097,000
deferred revenue—collaborative agreements																																				-3,215,000	-3,214,000	-3,215,000	-3,214,000
acquisition of business, net of cash acquired																																				1,880,000
direct financing arrangements repayments																																				0	0	-445,000	-320,000
effect of exchange rates on cash and cash equivalents																												-38,000	100,000	35,000		-3,000				0
net decrease in cash, cash equivalents, restricted cash and investments																														-5,060,000
december 31:
cash, cash equivalents, and marketable securities
working capital
year ended december 31:
cash provided by:
operating activities
investing activities
financing activities
restricted investments																																17,000	-41,000	-16,000		-11,000	13,877,000	110,000	135,000
net increase in cash and cash equivalents																																		-290,520,000				136,176,000								13,920,000	-7,612,000	41,757,000													72,885,000	-28,029,000	53,887,000	61,694,000	13,637,000	1,437,000	-97,060,000	79,983,000	-12,866,000	37,310,000				-27,344,000	53,456,000	-74,209,000	17,086,000	106,149,000		11,378,000	-12,291,000		-54,963,000	55,788,000
cash and cash equivalents at beginning of period																																0	0	652,343,000		0	0	521,439,000	0	0	0	452,297,000	0	0	471,429,000	0	0	224,057,000	0	0	273,164,000	0	0	417,912,000	0	0	449,824,000	0	0	178,767,000	0	0	108,854,000	0	0	18,861,000		0	0	11,494,000	0	0	0	132,180,000	0	0	0	29,698,000	0	0	22,928,000	0	0	43,368,000
cash and cash equivalents at end of period																																676,292,000	89,931,000	361,823,000		92,445,000	-169,961,000	657,615,000	75,638,000	6,120,000	17,859,000	421,822,000	-24,260,000	-30,321,000	436,585,000	13,920,000	-7,612,000	265,814,000	-18,480,000	25,708,000	231,855,000	-46,746,000	-18,769,000	377,843,000	-25,284,000	9,342,000	404,746,000	253,189,000	-24,809,000	139,098,000	72,885,000	-28,029,000	162,741,000	61,694,000	13,637,000	20,298,000		79,983,000	-12,866,000	48,804,000	-37,703,000	12,020,000	-67,659,000	104,836,000	53,456,000	-74,209,000	17,086,000	135,847,000	-7,708,000	11,378,000	10,637,000	-28,457,000	-54,963,000	99,156,000
net decrease in cash and cash equivalents																																							75,638,000
unrealized (gain) loss on long term investment
excess tax provision from stock-based compensation
long term investment
reclassification to additional paid in capital in connection with conversions or exchange of 4.75% convertible senior notes due 2015
unrealized gain on long term investment
excess tax benefit from stock-based compensation
depreciation and amortization of debt discounts																																						11,058,000	10,604,000	11,178,000	11,266,000	11,835,000	9,871,000	9,698,000	9,623,000	4,568,000	8,053,000	7,734,000	7,576,000	7,404,000	7,234,000
unrealized loss on long term investment																																						2,950,000	466,000
incomes taxes paid																																						14,000	-24,000	3,000	70,000	13,000
debt exchange expense on senior note conversions																																											0	0	265,000
loss on repurchase of convertible senior notes
excess tax benefit from stock based compensation																																							-778,000	-4,167,000	-1,760,000	3,833,000	43,000	0	31,000
proceeds from issuance of convertible senior notes, net of costs
repurchase of convertible senior notes
cash paid in connection with exchange of 4.75% convertible senior notes due 2015
foreign currency translation change
reclassification to common stock and additional paid in capital in connection with conversion of pfizer convertible subordinated note due 2014
reclassification to common stock and additional paid in capital in connection with conversions or exchanges of 4.75% convertible senior notes due 2015
reclassification to additional paid in capital in connection with repurchase of 4.75% convertible senior notes due 2015
purchase of property and equipment financed by direct financing lease																																											8,565,000	10,444,000	7,806,000
realized gain on marketable securities
long term investments
excess tax provision from stock based compensation
reclassification to additional paid in capital in connection with conversions or exchanges of 4.75% convertible senior notes due 2015																																								43,635,000
deferred revenue — collaborative agreements
direct financing arrangement repayments
release of restricted investments																																										125,000
reclassification to additional paid in capital in connection with exchange of 4.75% convertible senior notes due 2015																																											210,000	0	4,446,000
restricted cash
reclassification to additional paid in capital in connection with conversion of pfizer convertible subordinated note due 2014
realized gain on restricted cash and investments and marketable securities
debt exchange expense																																														1,491,000
accrued and other current liabilities																																																																										-9,080,000		10,968,000	-8,264,000	-7,127,000	-2,416,000	989,000	-20,893,000	-6,213,000	4,627,000	-15,433,000
deferred revenue — product revenues																																																		2,988,000	3,673,000
sales and maturities of marketable securities																																																136,000	157,000	97,000	167,000	339,000	530,000	576,000	1,321,000	10,272,000	6,822,000	6,123,000	4,024,000	3,161,000	9,537,000	4,184,000	89,630,000	94,549,000	60,045,000	30,879,000		118,515,000	67,803,000	322,192,000		102,679,000	129,894,000	85,074,000		136,305,000	87,136,000	323,068,000	206,350,000	227,321,000	174,113,000	202,864,000	207,791,000	186,724,000
non-cash reclassification to additional paid in capital in connection with conversion of pfizer convertible subordinated note due 2014
non-cash reclassification to additional paid in capital in connection with exchange of 4.75% convertible senior notes due 2015																																														31,322,000
paid in connection with exchange of 4.75% convertible senior notes due 2015
non-cash restructuring charges																																																				0						1,125,000	406,000	509,000			123,000		-73,000	107,000				201,000
loss on debt redemption																																																							0	0	3,988,000
realized gain on investments
deferred revenue																																																												10,000							-5,642,000	-5,589,000	-5,653,000	36,278,000				418,000	-499,000	649,000	-507,000	-2,371,000	-6,149,000	2,023,000	1,386,000	-1,341,000	-3,674,000	-3,514,000
redemption of convertible notes
impairment of marketable securities																																																										0
proceeds from issuance of common stock, net of offering costs
proceeds from issuance of convertible senior notes, net of offering costs
changes in restricted cash
loss on debt repurchases
repurchases of convertible senior notes and convertible subordinated notes
compensation expense on executive loans																																																																			0	0	0	18,000	57,000	0	0	18,000	19,000	18,000	19,000	19,000			98,000
realized gain on long-term investment
impairment of long-term investments																																																																											0	2,500,000	0	2,747,000	13,350,000	814,000	1,900,000
proceeds from issuance of convertible senior notes and convertible subordinated notes
realized loss on long-term investment
gain on sale of short-term investment
proceeds from issuance of pfizer convertible subordinated note																																																																					0	10,000,000
gain on sale of short term investment
gain from discontinued operations
non-cash restructuring charges and impairment of long-lived assets																																																																							1,236,000	299,000	447,000	342,000
gain on repurchase of convertible subordinated notes																																																																											0							0
gain on derivative financial instruments																																																																											-16,000	216,000
realized gain on long-term investments																																																																											0	0			-809,000	-434,000	-22,000	42,000	-125,000	-981,000
net cash from continuing operating activities																																																																						15,602,000				-26,082,000
net cash from discontinued activities																																																																										-191,000
proceeds from the sale of long-term investments																																																																											0	0			809,000			105,000	1,828,000	704,000
proceeds from the sale of equipment																																																																											137,000	767,000
sales of marketable securities
investing activities of discontinued operations
redemption/repurchase of convertible subordinated notes
net proceeds from issuance of convertible senior and subordinated notes
net proceeds from issuance of common stock
effect of exchange rate on cash and cash equivalents																																																																										-2,000	7,000	7,000	-4,000	61,000	-25,000	3,000	-33,000	12,000	-69,000	-179,000
cash and cash equivalents at beginning of year
cash and cash equivalents at end of year
taxes paid
income from discontinued operations
non-cash restructuring (credits) charges
loss on derivative financial instruments																																																																								2,000	-39,000	126,000				177,000
impairment of long term investments
net proceeds from sale of proteome facility and equipment																																																																								0
repurchase of convertible subordinated notes																																																																											0							0
(gain) loss on derivative financial instruments																																																																															-200,000			-155,000
non-cash purchased in-process research and development
net cash provided (used) in discontinued activities
acquisition of maxia pharmaceuticals, inc.																																																																																	-3,532,000
net proceeds from issuance of convertible subordinated notes																																																																											0	0	0	242,500,000
supplemental disclosure of non-cash activity:
reversal of deferred compensation
(income) income from discontinued operations																																																																										-153,000
realized gain on long term investments
net proceeds from sale of equipment
proceeds from sale of long term investments
investing activities of discontinued operation
realized gain on long term investments.
net proceeds from sale of proteome facility																																																																										59,000
loss on sale of assets
debt instruments and equity received in exchange for goods or services provided																																																																																		0
purchase of long-term investments
loans to executive officers																																																																																		0
non-cash other incomes																																																																												-17,003,000	39,553,000	2,626,000	0	0	393,000
stock compensation																																																																												121,000	122,000	125,000	286,000	498,000	501,000	1,081,000	867,000	1,461,000
acquisition of maxia pharmaceuticals, net of cash acquired																																																																															-989,000
impairment of prepaid and other assets
equity received in exchange for goods or services provided
changes in certain assets and liabilities:
purchased in-process research and development																																																																																0	28,116,000
compensation expense on loans to executive officers
long-term investments																																																																																			0	-5,000,000
cash from financing activities
(gain)/loss on derivative financial instruments																																																																																	45,000
cumulative effect of accounting change
impairment of assets
net cash provided (used in) in investing activities
gain/loss on derivative financial instruments																																																																																				-140,000
debt instruments or equity received in exchange for goods or services provided																																																																																				-2,688,000

We provide you with 20 years of cash flow statements for Incyte stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Incyte stock. Explore the full financial landscape of Incyte stock with our expertly curated income statements.

The information provided in this report about Incyte stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.